PTMS Human
Description
Overview of PTMS Human
PTMS Human (Parathymosin) is a recombinant human protein belonging to the pro/parathymosin family. It is expressed in Escherichia coli and purified for research applications. PTMS Human is a non-glycosylated polypeptide chain containing 125 amino acids (residues 1–102) with a molecular mass of 13.9 kDa . Its primary function involves modulating immune responses by antagonizing prothymosin alpha, potentially influencing resistance to opportunistic infections .
Recombinant Production and Purity
-
Source: E. coli
-
Formulation: 0.5 mg/ml in 20 mM Tris-HCl buffer (pH 8.0), 0.15 M NaCl, 20% glycerol, and 1 mM DTT
| Property | Value |
|---|---|
| Molecular Mass | 13.9 kDa |
| Amino Acid Residues | 125 (including His-tag) |
| Glycosylation | Non-glycosylated |
| Purification Method | Proprietary chromatography |
Biological Functions
PTMS Human is implicated in immune regulation, particularly through its interaction with prothymosin alpha. This interaction is hypothesized to block prothymosin alpha’s immunomodulatory effects, thereby influencing resistance to infections such as hepatitis B .
Disease Associations
PTMS Human is linked to two primary conditions:
-
Hepatitis B: Suggested role in modulating immune responses during viral infection .
-
Alzheimer’s Disease: Potential involvement in neurodegenerative pathways, though mechanistic details remain unclear .
Experimental Use
PTMS Human is primarily used in in vitro studies to investigate:
-
Immune function modulation
-
Protein-protein interaction mechanisms
-
Disease-specific signaling pathways
Stability Guidelines
Product Specs
Product Science Overview
Prothymosin alpha is an unstructured protein with a very low isoelectric point (pI 3.5), making it extremely acidic . The recombinant form of this protein is often produced in Escherichia coli (E. coli) and purified using conventional chromatography techniques . The recombinant human PTMA protein is typically fused to a His-tag at the N-terminus to facilitate purification .
Prothymosin alpha has both intracellular and extracellular functions. It is predominantly a nuclear protein but can also function in the cytoplasm and extracellularly . The specific localization of PTMA within cells, as well as the cell type and status, seemingly determine its function .
PTMA undergoes proteolytic modifications that are crucial for elucidating its interactions with other molecules . These interactions are essential for its roles in various physiological and pathological processes. For instance, PTMA has been shown to mediate immune function by conferring resistance to certain opportunistic infections .
Research has progressively attested to the clinical significance of Prothymosin alpha. It has been implicated in numerous pathological conditions, including various cancers, ischemic stroke, and immunomodulation . Additionally, PTMA variants have been identified with potent anti-HIV activity, highlighting its potential in antiviral therapies .
The differential localization patterns of PTMA in different tissues and cell types warrant further investigations to understand its interactions and proteolytic modifications under both normal and pathological conditions . The recombinant form of PTMA is used extensively in research to study its functions and potential therapeutic applications .
